Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Synopsys has surged 22% in a single week to $505.17, its strongest weekly move in recent memory, and the question now is whether positioning and analyst targets have adjusted fast enough to reflect where the stock actually is.
The analyst community has been moving in the right direction, though the pace of revisions still leaves the consensus price target at $570.57, roughly 13% above the current price. That gap was wider before a cluster of target lifts followed the September 30 earnings print. Wells Fargo raised to $540, Rosenblatt to $620, and Keybanc nudged to $605, all within the past week. The upgrades that preceded earnings, HSBC moving to Buy with a $700 target on September 25 and Morgan Stanley upgrading to Overweight on September 8, look prescient now. The analyst consensus score ranks in the 100th percentile relative to the broader universe, an extreme reading that reflects near-total directional agreement on the Street. The bull case rests on FY27 guidance of $11.15 billion revenue, ~44% operating margins, and $19.08 EPS, plus the $1 billion-plus AWS deal and an OpenAI partnership that expand the IP monetisation story. Bears counter with a Q3 backlog slipping to $10.9 billion from $11 billion in Q2, customer concentration at Intel, and what they see as go-to-market friction in software security. The EV/EBITDA multiple has expanded to 24.4x, up about 0.7x on the week and 3x on the PE basis over 30 days, so the stock is repricing fast while the bears' valuation-based caution has more surface area to work with.
Options positioning has shifted noticeably since the previous note. The put/call ratio was running well below its 20-day average ahead of earnings, reflecting appetite for calls rather than downside hedges. After the print and the subsequent rally, the PCR has edged back toward 0.93, still below the 20-day mean of 1.02 and roughly 0.7 standard deviations on the bullish side of normal. That is a softer bullish lean than the pre-earnings extreme, but the direction is intact. The 52-week range on the PCR runs from 0.43 to 1.35, so the current reading is comfortably in the middle. Borrow conditions remain entirely unconstraining. Availability is at roughly 3,050%, meaning there are around 30 shares available to borrow for every one already borrowed. That is down sharply from above 6,900% in late September, a tightening that reflects the jump in short interest, but the absolute level is still loose enough that new shorts face no friction. Cost to borrow is 0.43%, essentially unchanged from pre-earnings levels.
Short interest has rebuilt meaningfully around the earnings event. It rose about 17% on the week to 3.6% of the free float, up from 3.1% noted in the September 30 note and from roughly 2.4% in early September. The 30-day increase is 51%. That is a real and deliberate move, not noise, yet at 3.6% of float it still represents a modest position in absolute terms. Days to cover at 3.06 (per the most recent FINRA fortnightly data) leave no obvious squeeze pressure. This looks more like shorts rebuilding a position against a stock that has moved sharply than any conviction-driven directional bet.
The insider register adds one layer of note. The Deputy CFO and CAO, Sudhindra Kankanwadi, exercised options and sold shares across October 5 and 6, realising roughly $6 million in aggregate. The CEO, Ghazi Sassine, did the same on September 15 under a pre-arranged 10b5-1 plan, selling approximately $5.5 million worth. Planned sales under 10b5-1 programs carry far less signal than discretionary transactions, and the deputy CFO's trades this week do not appear to carry a 10b5-1 flag in the filing. Net insider sales over the past 90 days total around $44 million, consistent with a company where the stock has moved materially and executives are trimming into strength. Wikipedia attention for Synopsys is running at a z-score of 2.3 relative to its own 90-day history, the highest retail attention reading in recent months, which fits with a 22% weekly move attracting new interest.
The closest peer, CDNS, rose 10.9% on the week, so Synopsys outperformed its nearest correlate by roughly 11 percentage points. ADSK added 13.8% on the week, also strong but well behind. That relative outperformance matters because it means Synopsys-specific factors, guidance, the AWS deal, the analyst upgrades, drove the bulk of the move rather than a broad software re-rating. The next earnings event is scheduled for December 2, 56 days out.
What to watch from here is whether the analyst target distribution catches up with the stock, how quickly the $570 consensus mean gets revised, and whether shorts holding at 3.6% of float add to their positions or cover as the stock consolidates around the $505 level.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
